nach oben

Clinical & Experimental Metastasis

Erschienen in:

13.06.2019 | Research Paper

Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC

verfasst von: Ziqiang Tian, Zhenhua Li, Yonggang Zhu, Lingjiao Meng, Fei Liu, Meixiang Sang, Guiying Wang

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidences indicated that some microRNAs (miRNAs) play a critical role during the carcinogenesis. In the present study, we found that miR-124 is down-regulated in esophageal squamous cell carcinoma (ESCC) tissues. Three miR-124 encoding genes, including mir-124-1, mir-124-2, and mir-124-3, harboring CpG islands undergo methylation-mediated miR-124 inactivation in ESCC tissues. The methylation status of all these three genes was negatively associated with the expression of miR-124. The low expression of miR-124 and the hypermethylation of mir-124-1 and mir-124-3 were associated with the clinico-pathological parameters indicating the poor prognosis. In addition, promoter methylation of all three genes plus low expression of miR-124 was the independent poor prognostic marker for ESCC patients. In conclusion, miR-124 may function as a tumor suppressive miRNA, and hypermethylation-mediated inactivation of miR-124 may be useful for a poor prognostic marker for ESCC patients.

Nur mit Berechtigung zugänglich

Siegel RL et al (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefPubMed

Kaz AM et al (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342:193–199CrossRefPubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

He L et al (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531CrossRefPubMed

Di Leva G et al (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314CrossRefPubMed

Samantarrai D et al (2013) Genomic and epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer. Mol Cancer Res 11:315–328CrossRefPubMed

Lu L et al (2007) Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67:10117–10122CrossRefPubMed

Han L et al (2007) DNA methylation regulates microRNA expression. Cancer Biol Ther 6:1284–1288PubMed

Lujambio A et al (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105:13556–13561CrossRefPubMedPubMedCentral

10.

Wang Y et al (2016) miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL. BMC Cancer 16:826CrossRefPubMedPubMedCentral

11.

Geng S et al (2014) The tumor suppressor role of miR-124 in osteosarcoma. PLoS ONE 9:e91566CrossRefPubMedPubMedCentral

12.

Ueda Y et al (2014) DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. Dig Dis Sci 59:2444–2451CrossRefPubMed

13.

Wang H et al (2017) Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome. Clin Epigenet 9:91CrossRef

14.

Mathé EA et al (2009) MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15:6192–6200CrossRefPubMedPubMedCentral

15.

Sauvageau M et al (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7:299–313CrossRefPubMedPubMedCentral

16.

Dong F et al (2017) Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure. Oncotarget 8:27547–27568PubMedPubMedCentral

17.

Jafri MA et al (2017) Role of miRNAs in human cancer metastasis: implications for therapeutic intervention. Semin Cancer Biol 44:117–131CrossRefPubMed

18.

Ma T et al (2016) MicroRNA-124 functions as a tumor suppressor by regulating CDH2 and epithelial-mesenchymal transition in non-small cell lung cancer. Cell Physiol Biochem 38:1563–1574CrossRefPubMed

19.

Li W et al (2017) miR-124 acts as a tumor suppressor in glioblastoma via the inhibition of signal transducer and activator of transcription 3. Mol Neurobiol 54:2555–2561CrossRefPubMed

20.

Zhao Y et al (2017) MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. Oncotarget 8:25005–25020PubMedPubMedCentral

21.

Wang P et al (2014) Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33:514–524CrossRefPubMed

22.

Wilting SM et al (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 9:167CrossRefPubMedPubMedCentral

23.

Gebauer K et al (2013) Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer 108:131–138CrossRefPubMedPubMedCentral

24.

Asada K et al (2015) Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 64:388–396CrossRefPubMed

25.

Liu F et al (2016) Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients. Biomarkers 21:80–90CrossRefPubMed

26.

Okamoto K et al (2016) Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy. Oncol Rep 36:3333–3342CrossRefPubMed

27.

Lin Y et al (2017) P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma. Dis Esophagus 30:1–10PubMed

28.

Wang Y et al (2017) MicroRNA expression in esophageal squamous cell carcinoma: novel diagnostic and prognostic biomarkers. Mol Med Rep 15:3833–3839CrossRefPubMed

29.

Wu X et al (2017) NORAD expression is associated with adverse prognosis in esophageal squamous cell carcinoma. Oncol Res Treat 40:370–374CrossRefPubMed

30.

Yang XZ et al (2018) Predictive value of LINC01133 for unfavorable prognosis was impacted by alcohol in esophageal squamous cell carcinoma. Cell Physiol Biochem 48:251–262CrossRefPubMed

31.

Kang K et al (2018) Expression of UCA1 and MALAT1 long-chain non-coding RNAs in esophageal squamous cell carcinoma tissues is predictive of patient prognosis. Arch Med Sci 14:752–759PubMedPubMedCentral

32.

Bao J et al (2018) Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Biomark 21:527–533CrossRefPubMed

33.

Xia W et al (2016) Circular RNA has_circ_0067934 is upregulated in esophageal squamous cell carcinoma and promoted proliferation. Sci Rep 6:35576CrossRefPubMedPubMedCentral

34.

Agirre X et al (2009) Epigenetic silencing of the tumor suppressor microRNA HsamiR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69:4443–4453CrossRefPubMed

35.

Shi XB et al (2015) miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. Cancer Res 75:5309–5317CrossRefPubMedPubMedCentral

36.

Zheng F et al (2012) The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61:278–289CrossRefPubMed

37.

Qiao W et al (2017) miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys Res Commun 486:43–48CrossRefPubMed

38.

Liu S et al (2016) miR-124 inhibits proliferation and invasion of human retinoblastoma cells by targeting STAT3. Oncol Rep 36:2398–2404CrossRefPubMed

Titel: Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC
verfasst von: Ziqiang Tian
Zhenhua Li
Yonggang Zhu
Lingjiao Meng
Fei Liu
Meixiang Sang
Guiying Wang
Publikationsdatum: 13.06.2019
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 4/2019
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-09974-1

Springer Medizin

Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study

The importance of developing therapies targeting the biological spectrum of metastatic disease

CTHRC1 promotes M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-Akt signaling pathway

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy

Identification of S100A14 as a metastasis-promoting molecule in a murine organotropic metastasis model

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie